Protagonist Therapeutics (PTGX) Change in Receivables (2017 - 2024)
Historic Change in Receivables for Protagonist Therapeutics (PTGX) over the last 8 years, with Q4 2024 value amounting to $165.0 million.
- Protagonist Therapeutics' Change in Receivables rose 155000.0% to $165.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $155.0 million, marking a year-over-year increase of 145155.16%. This contributed to the annual value of $155.0 million for FY2024, which is 145155.16% up from last year.
- According to the latest figures from Q4 2024, Protagonist Therapeutics' Change in Receivables is $165.0 million, which was up 155000.0% from -$43000.0 recorded in Q3 2024.
- In the past 5 years, Protagonist Therapeutics' Change in Receivables ranged from a high of $290.0 million in Q1 2024 and a low of -$300.0 million during Q2 2024
- In the last 5 years, Protagonist Therapeutics' Change in Receivables had a median value of -$41000.0 in 2023 and averaged $7.9 million.
- Within the past 5 years, the most significant YoY rise in Protagonist Therapeutics' Change in Receivables was 70732195.12% (2024), while the steepest drop was 249990000.0% (2024).
- Quarter analysis of 5 years shows Protagonist Therapeutics' Change in Receivables stood at -$363000.0 in 2020, then crashed by 195.32% to -$1.1 million in 2021, then surged by 89.27% to -$115000.0 in 2022, then skyrocketed by 8795.65% to $10.0 million in 2023, then skyrocketed by 1550.0% to $165.0 million in 2024.
- Its Change in Receivables stands at $165.0 million for Q4 2024, versus -$43000.0 for Q3 2024 and -$300.0 million for Q2 2024.